Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5799141 | 0.93 | L3MBTL1 (0.53) | L3MBTL1SMN1; SMN2KEAP1SIGMAR1CYP2D6 | |
| SCHEMBL829653 | 0.88 | L3MBTL1 (0.50) | L3MBTL1SMN1; SMN2KEAP1ALOX15SIGMAR1 | |
| Urea SCHEMBL11526333 | 0.87 | KEAP1 (0.54) | L3MBTL1SMN1; SMN2KEAP1ALOX15SIGMAR1 | |
| SCHEMBL8860545 | 0.87 | L3MBTL1 (0.77) | L3MBTL1SMN1; SMN2ALOX15PAOXCYP1A2 | |
| SCHEMBL11598668 | 0.87 | L3MBTL1 (0.77) | L3MBTL1SMN1; SMN2ALOX15PAOXCYP1A2 | |
| SCHEMBL24003654 | 0.83 | KDM4E (0.50) | L3MBTL1SMN1; SMN2KEAP1ALOX15SIGMAR1 | |
| SCHEMBL14392151 | 0.79 | KEAP1 (0.47) | SMN1; SMN2KEAP1ALOX15SIGMAR1CYP2D6 | |
| Adipic Acid SCHEMBL22723323 | 0.79 | CYP2D6 (0.60) | SMN1; SMN2KEAP1ALOX15SIGMAR1CYP2D6 | |
| Adipic Acid SCHEMBL1228726 | 0.79 | CYP2D6 (0.60) | SMN1; SMN2KEAP1ALOX15SIGMAR1CYP2D6 | |
| SCHEMBL1616800 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562842-B2 | Use of polyaminoisoprenyl derivatives in antibiotic or antiseptic treatment | UNIVERSITE D'AIX-MARSEILLE (FR) | 2020-02-18 | — | — | US | claimed |
| EP-2678307-B1 | USE OF POLYAMINOISOPRENYL DERIVATIVES IN ANTIBIOTIC OR ANTISEPTIC TREATMENT | UNIV AIX MARSEILLE (FR) | 2018-04-04 | — | — | EP | claimed |
| US-20170015617-A1 | USE OF POLYAMINOISOPRENYL DERIVATIVES IN ANTIBIOTIC OR ANTISEPTIC TREATMENT | UNIVERSITE D'AIX-MARSEILLE (FR) | 2017-01-19 | — | — | US | claimed |
| US-20140128335-A1 | USE OF POLYAMINOISOPRENYL DERIVATIVES IN ANTIBIOTIC OR ANTISEPTIC TREATMENT | UNIVERSITE D'AIX-MARSEILLE (FR) | 2014-05-08 | — | — | US | claimed |
| EP-2678307-A1 | USE OF POLYAMINOISOPRENYL DERIVATIVES IN ANTIBIOTIC OR ANTISEPTIC TREATMENT | Université d'Aix-Marseille (FR) | 2014-01-01 | — | — | EP | claimed |
| WO-2012113891-A1 | USE OF POLYAMINOISOPRENYL DERIVATIVES IN ANTIBIOTIC OR ANTISEPTIC TREATMENT | UNIVERSITE D'AIX-MARSEILLE (FR) | 2012-08-30 | — | — | WO | claimed |
| US-10562842-B2 | Use of polyaminoisoprenyl derivatives in antibiotic or antiseptic treatment | UNIVERSITE D'AIX-MARSEILLE (FR) | 2020-02-18 | — | — | US | disclosed |
| EP-2678307-B1 | USE OF POLYAMINOISOPRENYL DERIVATIVES IN ANTIBIOTIC OR ANTISEPTIC TREATMENT | UNIV AIX MARSEILLE (FR) | 2018-04-04 | — | — | EP | disclosed |
| US-20170015617-A1 | USE OF POLYAMINOISOPRENYL DERIVATIVES IN ANTIBIOTIC OR ANTISEPTIC TREATMENT | UNIVERSITE D'AIX-MARSEILLE (FR) | 2017-01-19 | — | — | US | disclosed |
| US-9464032-B2 | Use of polyaminoisoprenyl derivatives in antibiotic or antiseptic treatment | UNIVERSITE D'AIX-MARSEILLE (FR) | 2016-10-11 | — | — | US | disclosed |
| US-20140128335-A1 | USE OF POLYAMINOISOPRENYL DERIVATIVES IN ANTIBIOTIC OR ANTISEPTIC TREATMENT | UNIVERSITE D'AIX-MARSEILLE (FR) | 2014-05-08 | — | — | US | disclosed |
| US-20090221821-A1 | ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC MA INC. (US) | 2009-09-03 | — | — | US | disclosed |
| US-7579354-B2 | Adenosine receptor antagonists and methods of making and using the same | KIESMAN WILLIAM F | 2009-08-25 | — | — | US | disclosed |
| EP-1230243-B1 | POYCYLOALKYLPURINES AS ADENOSINE RECEPTOR ANTAGONISTS | BIOGEN IDEC INC (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20070015732-A1 | Adenosine receptor antagonists and methods of making and using the same | KIESMAN WILLIAM F | 2007-01-18 | — | — | US | disclosed |
| US-20060252730-A1 | Adenosine receptor antagonists and methods of making and using the same | KIESMAN WILLIAM F | 2006-11-09 | — | — | US | disclosed |
| US-20040067966-A1 | Adenosine receptor antagonists and methods of making and using the same | BIOGEN, INC. | 2004-04-08 | — | — | US | disclosed |
| US-6649600-B1 | 2,6-Dioxo or dithioxy-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo derivatives; highly potent and selective diuretics | BIOGEN, INC. | 2003-11-18 | — | — | US | disclosed |
| EP-1230243-A1 | POYCYLOALKYLPURINES AS ADENOSINE RECEPTOR ANTAGONISTS | BIOGEN, INC. (US) | 2002-08-14 | — | — | EP | disclosed |
| WO-2001034610-A1 | POLYCYCLOALKYLPURINES AS ADENOSINE RECEPTOR ANTAGONISTS | BIOGEN, INC. (US) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221821-A1 | ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME | ADORA1, ADORA2A, ADORA3 | L3MBTL1 2154/4885SMN1; SMN2 1007/4885KEAP1 1197/4885 |
| US-20060252730-A1 | Adenosine receptor antagonists and methods of making and using the same | ADORA1, ADORA2A, ADORA3 | L3MBTL1 2154/4885SMN1; SMN2 1007/4885KEAP1 1197/4885 |
| US-20070015732-A1 | Adenosine receptor antagonists and methods of making and using the same | ADORA1, ADORA2A, ADORA3 | L3MBTL1 2154/4885SMN1; SMN2 1007/4885KEAP1 1197/4885 |
| US-20140128335-A1 | USE OF POLYAMINOISOPRENYL DERIVATIVES IN ANTIBIOTIC OR ANTISEPTIC TREATMENT | ABCC1, ABCB11, ABCB1 | L3MBTL1 4203/4885SMN1; SMN2 4878/4885KEAP1 1273/4885 |
| US-20040067966-A1 | Adenosine receptor antagonists and methods of making and using the same | ADORA1, ADORA2A, ADORA3 | L3MBTL1 2518/4885SMN1; SMN2 1001/4885KEAP1 1183/4885 |
| US-20170015617-A1 | USE OF POLYAMINOISOPRENYL DERIVATIVES IN ANTIBIOTIC OR ANTISEPTIC TREATMENT | ABCC1, ABCB11, ABCB1 | L3MBTL1 4203/4885SMN1; SMN2 4878/4885KEAP1 1273/4885 |
| US-10562842-B2 | Use of polyaminoisoprenyl derivatives in antibiotic or antiseptic treatment | ABCC1, ABCB11, ABCB1 | L3MBTL1 4203/4885SMN1; SMN2 4878/4885KEAP1 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.